Adaptive Biotechnologies
Adaptive Biotechnologies is a Seattle-based, NASDAQ-listed biotechnology company that translates adaptive immune system genetics into clinical diagnostics and pharma discovery tools, anchored by its FDA-cleared clonoSEQ MRD test for blood cancers and an immune receptor data platform serving biopharma partners.
- Company typePublic
- Founded2009
- HeadquartersSeattle, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What Adaptive Biotechnologies does
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company founded in 2009 and headquartered in Seattle, Washington, that translates the genetics of the adaptive immune system into clinical diagnostics and therapeutic discovery tools. Its core commercial product is clonoSEQ, the first FDA-cleared next-generation sequencing assay for minimal residual disease (MRD) monitoring, currently reimbursed for multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and more recently mantle cell lymphoma (MCL) under Medicare. The clonoSEQ assay detects residual cancer cells in bone marrow or blood at a sensitivity of one in a million cells (10⁻⁶) and is ordered by oncologists and hematologists for treatment-response assessment and disease-progression monitoring, with test volume reaching 105,587 in 2025.
The company's second business line is its Immune Medicine Platform, which combines immunosequencing, proprietary TCR-antigen mapping, and AI/ML to decode T-cell and B-cell receptor sequences against disease-specific antigens. The platform underpins the immuneCODE database and supports pharma partnerships for target discovery and clinical-trial biomarkers, most notably two December 2025 agreements with Pfizer with up to $890 million in potential milestone payments.
Adaptive generates revenue primarily through clinical diagnostic testing services billed to Medicare and commercial payers at an average selling price of approximately $1,400 per clonoSEQ test, supplemented by biopharma services (MRD testing and immune monitoring for clinical trials) and non-exclusive immune-receptor data licensing agreements with pharmaceutical partners. The MRD business contributed $212 million of 2025 revenue and reached positive adjusted EBITDA of $15 million, while full-year 2025 total revenue reached $277 million (55% YoY growth). The company operates a U.S.-focused direct sales and CLIA-certified laboratory model, with plans to expand internationally through technology transfer partnerships and to separate the MRD and Immune Medicine businesses into two distinct entities by year-end 2026.
Adaptive Biotechnologies firmographics
Firmographics- Name
- Adaptive Biotechnologies
- Legal name
- Adaptive Biotechnologies Corporation
- Website
- https://adaptivebiotech.com
- Company type
- Public
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Adaptive Biotechnologies is a Seattle-based, NASDAQ-listed biotechnology company that translates adaptive immune system genetics into clinical diagnostics and pharma discovery tools, anchored by its FDA-cleared clonoSEQ MRD test for blood cancers and an immune receptor data platform serving biopharma partners.
- Ownership category
- akta.pro rank
Adaptive Biotechnologies industry classification
Industry- Product category
- Clinical Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK), High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)
Keywords
Where Adaptive Biotechnologies is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Adaptive Biotechnologies business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- MRD Testing (clonoSEQ): Revenue from clinical diagnostic testing services using clonoSEQ assay for minimal residual disease monitoring in blood cancer patients. Tests are ordered by oncologists and hematologists for patient monitoring during and after treatment. Q1 2026 MRD revenue was $67.1 million, representing 95% of total revenue.
- Pharma Partnerships - Immune Receptor Licensing: Non-exclusive licensing agreements with pharmaceutical companies for T-cell receptor discovery and immune receptor data. December 2025 Pfizer agreements worth up to $890 million in potential milestone payments plus upfront payments. Includes target discovery partnership and data licensing for AI-driven drug discovery.
- Biopharma Services: Services provided to pharmaceutical companies for clinical trials including MRD testing in drug development, immune monitoring, and clinical trial support. Growing pharma trial backlog supporting MRD-led growth.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | clonoSEQ MRD test - clinical diagnostic pricing |
| Other | Multi-year contract | Pharma partnership and licensing agreements |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Adaptive Biotechnologies product offering
Product offeringCore offering
Adaptive Biotechnologies translates the scale and precision of the adaptive immune system into clinical diagnostics and immune profiling products. Its core commercial offering is clonoSEQ, an FDA-cleared NGS-based minimal residual disease (MRD) test that detects and monitors residual cancer cells in blood and bone marrow for multiple myeloma, B-ALL, CLL, and other lymphoid malignancies. The company also operates an Immune Medicine Platform that maps T-cell receptors to disease-specific antigens, enabling data licensing and target discovery partnerships with pharmaceutical companies.
Product overview
Adaptive Biotechnologies operates a dual-segment business centered on its Immune Medicine Platform, which encompasses two core products: clonoSEQ and the Immune Medicine discovery business. clonoSEQ is an FDA-cleared NGS-based MRD test for measuring residual cancer cells in blood cancers, while the Immune Medicine Platform uses immune repertoire sequencing and AI-driven TCR-antigen models to support drug discovery and biopharma partnerships. The company recently announced plans to separate these two businesses into distinct entities. Key offerings include T-Detect COVID (a T-cell diagnostic for prior SARS-CoV-2 infection), immunoSEQ T-MAP COVID (a vaccine monitoring tool), and the newly launched Digital Biotechnologies subsidiary.
Differentiator
Problem solved
Functional benefit
Brands
- clonoSEQ: FDA-cleared NGS-based MRD test for measuring residual disease in blood cancers including multiple myeloma, B-ALL, and CLL
- T-Detect
- immunoSEQ
- immuneCODE
Products and services
- clonoSEQ FDA-cleared NGS-based minimal residual disease (MRD) test that detects and monitors residual cancer cells in bone marrow and blood samples from patients with multiple myeloma, B-ALL, CLL, and other lymphoid malignancies at a sensitivity of 1 in 1,000,000 cells. Ordered by oncologists and hematologists, processed through Adaptive's CLIA-certified lab, and reimbursed by Medicare and commercial insurance.
- Immune Medicine Platform Proprietary immune repertoire sequencing platform that maps T-cell receptors (TCRs) to disease-specific antigens, enabling drug discovery partnerships and AI-driven target identification for immunology applications. Anchored by a database of over 6 million functional TCR-antigen pairs and used by pharmaceutical companies such as Pfizer for AI-driven drug discovery and TCR target identification.
- T-Detect COVID T-cell based clinical diagnostic test that detects prior SARS-CoV-2 infection by identifying virus-specific T-cell signatures in blood, offering higher sensitivity and durability than antibody serology testing.
- immunoSEQ T-MAP COVID Molecular T-cell monitoring tool for vaccine developers that maps TCRs to SARS-CoV-2 antigens, enabling quantitative measurement of T-cell immune response to vaccines and tracking of response persistence over time.
Quantifiable outcome
- Patients with undetectable MRD had nearly 7-fold decreased risk of disease progression compared to MRD-positive patients
- +3 more outcomes
Companies that use Adaptive Biotechnologies
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles2 records
Adaptive Biotechnologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability4 records
Feature5 records
Adaptive Biotechnologies partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Pfizer Inc.coreTwo non-exclusive licensing agreements: (1) T-cell receptor target discovery partnership for rheumatoid arthritis where Adaptive identifies disease-specific TCRs and Pfizer handles development and commercialization; (2) Data licensing agreement for Adaptive's proprietary TCR-antigen binding datasets to accelerate Pfizer's AI-driven drug discovery. Total potential milestone payments up to $890 million.
- NeoGenomicsminorExclusive multi-year MRD collaboration announced in 2026 for liquid biopsy and NGS panel offerings. NeoGenomics will offer MRD testing services using Adaptive's technology.
- ACCC (Association of Community Cancer Centers)minorSponsor partnership for MRD education initiatives targeting community oncology practices. Joint development of MRD Testing Implementation Roadmap for CLL and multiple myeloma.
- NCODA (National Community Oncology Dispensing Association)minorPartnership for MRD education in community oncology. NCODA published Positive Quality Intervention for clonoSEQ in CLL.
Scale indicators15 records
Recent moves7 records
Expansion highlights6 records
Adaptive Biotechnologies competitors and assessment
Company assessmentDirect peers
- Natera: Natera markets Signatera, a leading tumor-informed NGS-based MRD test used in solid tumor monitoring and clinical trials. It is the most direct competitor to Adaptive's clonoSEQ in the MRD testing category, serving oncologists and biopharma sponsors with overlapping clinical use cases.
- NeoGenomics: NeoGenomics provides oncology testing including liquid biopsy and NGS panels, and signed an exclusive multi-year MRD collaboration with Adaptive in 2026. It is both a partner and adjacent competitor in the community oncology MRD/liquid biopsy segment.
- Guardant Health: Guardant Health offers liquid biopsy-based oncology tests (Guardant360, Guardant Reveal MRD) for solid tumors. It competes with Adaptive in oncology diagnostics and shares the same hospital and biopharma customer base for cancer recurrence and monitoring.
Broad incumbents
- Foundation Medicine: Foundation Medicine (a Roche subsidiary) is a leading provider of comprehensive genomic profiling in oncology. It overlaps with Adaptive's immune profiling and biopharma services and serves many of the same academic cancer centers and pharma sponsors at broader scale.
- Exact Sciences: Exact Sciences is a large cancer diagnostics company known for Cologuard and the Oncotype franchise. It is a broader incumbent in oncology screening and recurrence monitoring, competing for oncologist mind-share and biopharma services revenue.
- Myriad Genetics: Myriad Genetics offers hereditary cancer and tumor profiling tests serving oncologists and urologists. While its focus is broader genetic testing, it competes for the same clinician customers and biopharma partnership economics.
Emerging players
- Tempus AI: Tempus AI combines genomic sequencing with AI-driven analytics for oncology and biopharma customers. Its AI platform, MRD-adjacent offerings, and pharma partnerships overlap with Adaptive's Immune Medicine business in particular.
- Personalis: Personalis is a cancer genomics company offering tumor and immune profiling for biopharma R&D and clinical trials. It overlaps with Adaptive's Immune Medicine/biopharma services segment around TCR-based and immune profiling data for pharma customers.
- Caris Life Sciences: Caris provides molecular profiling and AI-driven oncology diagnostics, including liquid biopsy offerings that overlap with MRD monitoring. It targets similar oncologist and biopharma customer segments and represents an emerging competitor in cancer recurrence testing.
Others
- 10x Genomics: 10x Genomics provides single-cell and immune receptor sequencing tools that enable research applications. It is an enabling/infrastructure provider for the same immune sequencing ecosystem in which Adaptive operates rather than a direct competitor in MRD.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Adaptive Biotechnologies social profiles
Digital presenceAdaptive Biotechnologies compliance and trust
Trust signalCompliance3 records
Adaptive Biotechnologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Adaptive Biotechnologies leadership team
Management profileNumber of profiles
Profiles10 records
Adaptive Biotechnologies subsidiaries and ownership
Company hierarchySubsidiaries1 record
Adaptive Biotechnologies funding detail
Funding detailFunding overview
Funding rounds13 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Adaptive Biotechnologies M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Adaptive Biotechnologies
What does Adaptive Biotechnologies do?
Adaptive Biotechnologies translates the scale and precision of the adaptive immune system into clinical diagnostics and immune profiling products. Its core commercial offering is clonoSEQ, an FDA-cleared NGS-based minimal residual disease (MRD) test that detects and monitors residual cancer cells in blood and bone marrow for multiple myeloma, B-ALL, CLL, and other lymphoid malignancies. The company also operates an Immune Medicine Platform that maps T-cell receptors to disease-specific antigens, enabling data licensing and target discovery partnerships with pharmaceutical companies.
Is Adaptive Biotechnologies a public or private company?
Adaptive Biotechnologies is a public company. It is classified as public and is currently operating.
When was Adaptive Biotechnologies founded?
Adaptive Biotechnologies was founded in 2009. It employs 501 to 1,000 people.
Where is Adaptive Biotechnologies based?
Adaptive Biotechnologies is headquartered in Seattle, United States, in the North America region.
How does Adaptive Biotechnologies make money?
Three revenue lines are on record. MRD Testing (clonoSEQ) is the primary driver. The others are pharma Partnerships - Immune Receptor Licensing and biopharma Services.
Who are Adaptive Biotechnologies's main competitors?
Direct peers on record are Natera, NeoGenomics and Guardant Health. Broad incumbents are Foundation Medicine, Exact Sciences and Myriad Genetics. Emerging players are Tempus AI, Personalis and Caris Life Sciences. 10x Genomics is listed as an others.
Does Adaptive Biotechnologies have an API?
No public API is recorded for Adaptive Biotechnologies.
What industry is Adaptive Biotechnologies in?
Adaptive Biotechnologies's product category is Clinical Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 325413 and its SIC code is 2835.